MYX 0.66% $4.60 mayne pharma group limited

and the company spent over extra US$20m expense/per year,...

  1. 7,125 Posts.
    lightbulb Created with Sketch. 546
    and the company spent over extra US$20m expense/per year, immediately after the acquisition, to support the products but mainly on IMVEXXY.
    Annovera's patent expiring is approaching.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.